StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Halozyme Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was 24.9%. For fiscal 2025 it was 22.7%, against 43.7% the year before. The highest annual figure on record is 90.8% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202522.7%−21.0
FY2024Dec 31, 202443.7%+9.8
FY2023Dec 31, 202334.0%+3.3
FY2022Dec 31, 202230.6%−60.2
FY2021Dec 31, 202190.8%+42.6
FY2020Dec 31, 202048.2%+85.1
FY2019Dec 31, 2019-36.9%+16.0
FY2018Dec 31, 2018-52.9%−72.8
FY2017Dec 31, 201719.9%+90.1
FY2016Dec 31, 2016-70.2%−46.4
FY2015Dec 31, 2015-23.9%+66.9
FY2014Dec 31, 2014-90.8%+61.6
FY2013Dec 31, 2013-152.3%−25.8
FY2012Dec 31, 2012-126.5%−91.3
FY2011Dec 31, 2011-35.2%+355.5
FY2010Dec 31, 2010-390.8%+36.1
FY2009Dec 31, 2009-426.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202647.8%−2.9
Q1 FY2026Mar 31, 202639.8%−4.8
Q4 FY2025Dec 31, 2025-31.3%−77.3
Q3 FY2025Sep 30, 202549.5%+2.2
Q2 FY2025Jun 30, 202550.7%+10.4
Q1 FY2025Mar 31, 202544.6%+5.4
Q4 FY2024Dec 31, 202446.0%+8.9
Q3 FY2024Sep 30, 202447.2%+9.3
Q2 FY2024Jun 30, 202440.3%+6.5
Q1 FY2024Mar 31, 202439.2%+14.8
Q4 FY2023Dec 31, 202337.1%+5.3
Q3 FY2023Sep 30, 202337.9%+8.4
Q2 FY2023Jun 30, 202333.8%+18.9
Q1 FY2023Mar 31, 202324.4%−26.8
Q4 FY2022Dec 31, 202231.8%−33.7
Q3 FY2022Sep 30, 202229.5%−157.5
Q2 FY2022Jun 30, 202214.9%−52.1
Q1 FY2022Mar 31, 202251.3%+19.9
Q4 FY2021Dec 31, 202165.5%+5.3
Q3 FY2021Sep 30, 2021187.0%+131.6
Q2 FY2021Jun 30, 202167.0%+20.3
Q1 FY2021Mar 31, 202131.3%+55.4
Q4 FY2020Dec 31, 202060.1%+124.2
Q3 FY2020Sep 30, 202055.4%+109.5
Q2 FY2020Jun 30, 202046.8%+84.1
Q1 FY2020Mar 31, 2020-24.1%−27.2
Q4 FY2019Dec 31, 2019-64.1%−60.6
Q3 FY2019Sep 30, 2019-54.1%+54.9
Q2 FY2019Jun 30, 2019-37.4%+27.7
Q1 FY2019Mar 31, 20193.2%+92.1
Q4 FY2018Dec 31, 2018-3.5%−68.9
Q3 FY2018Sep 30, 2018-109.0%−113.3
Q2 FY2018Jun 30, 2018-65.0%+26.1
Q1 FY2018Mar 31, 2018-89.0%+22.3
Q4 FY2017Dec 31, 201765.4%+135.6
Q3 FY2017Sep 30, 20174.3%+95.2
Q2 FY2017Jun 30, 2017-91.1%–
Q1 FY2017Mar 31, 2017-111.3%–
Q4 FY2016Dec 31, 2016-70.2%–
Q3 FY2016Sep 30, 2016-90.9%–

More Halozyme Therapeutics figures

See a number that looks wrong?